Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$23.03M-0.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean E. Browne
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 151
- Beta
- -0.15
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.34
Financials
Revenue
$23.03M-0.3%Net Income
$-9.41MEBITDA
$-8.29M-5035.6%Free Cash Flow
$-7.55MEPS (diluted)
$-0.07Shares Outstanding (diluted)
140.26M+12453.7%Operating Expenses
$17.50MCash & Debt
$9.87MReturn of Capital
$0.00Revenue by Segment (annual)
$133.93MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $133.93M | $4.97M | $0.04 |
| 2024 | $117.27M | $-16.45M | $-0.12 |
| 2023 | $91.30M | $660.0K | $0.01 |
| 2022 | $57.97M | $-8.48M | $-0.09 |
| 2021 | $55.26M | $-4.85M | $-0.06 |
| 2020 | $53.34M | $-7.02M | $-0.25 |
| 2019 | $64.68M | $-8.22M | $-0.62 |
| 2018 | $72.20M | $-70.10M | $-5.97 |
| 2017 | $82.61M | $-52.41M | $-34.76 |
| 2016 | $90.00M | $-19.49M | $-18.46 |
| 2015 | $59.35M | $-2.17M | $-2.62 |
| 2014 | $35.33M | $-10.51M | $-19.26 |
| 2013 | $33.07M | $-12.69M | $-29.15 |
| 2012 | $32.98M | $-7.71M | $-19.83 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.05
- Implied price
- $1.05
- Return from $0.35
- 24.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.52 — today's price is already 32.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.0% | 5.0% | 9.2% | 12.8% | 16.0% | 18.9% |
| 3.0% | 10.4% | 14.7% | 18.5% | 21.9% | 24.9% |
| 8.0% | 15.7% | 20.3% | 24.3% | 27.8% | 31.0% |
| 13.0% | 21.1% | 25.9% | 30.0% | 33.7% | 37.1% |
| 18.0% | 26.4% | 31.5% | 35.8% | 39.6% | 43.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (3)
- Newsprnewswire.com·40d ago·Neutral
…ogy, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™ BELGRADE, Mont., Aug. 27, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced an exclusive partnership with BioHorizons (a Henry Schein, Inc. company), whereby BioHorizons will distribute Xtant's allogeneic growth factor technology under the private brand Prolif…
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·56d ago·Neutral
Xtant Medical Reports Second Quarter 2026 Financial Results Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast today, August 11 th, at 8:30am ET BELGRADE, Mont., Aug. 11, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.03 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.07 vs $-0.02miss
- Wed, May 13$-0.02 vs $-0.01miss
- Tue, Mar 31$0.00 vs $-0.00beat
- Mon, Nov 10$0.01 vs $-0.01beat
- Tue, Aug 12$0.02 vs $-0.01beat
- Mon, May 12$0.00 vs $-0.01beat
Estimates and results for XTNT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XTNT officers and directors.
- Bought
- $1.1m
- Sold
- $7.3m
3 trades
7 trades
- Orbimed Advisors Llcsold
- Brandt Kevin Dbought
- Neils Scott Csold
- Browne Sean Esold
- Browne Sean Esold
- Vizirgianakis Stavros G.bought
- Vizirgianakis Stavros G.bought
- Brandt Kevin Dsold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XTNT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.